Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bluestar-Endometrial01: AZD8205 vs chemotherapy in B7-H4–selected advanced/metastatic endometrial cancer
jRCT2011250034Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, open-label trial of puxitatug samrotecan in endometrial cancer (EC) and endometrial carcinosarcoma (2 arms), sponsored by AstraZeneca. Primary endpoints: Progression-free survival and Overall survival. Started Sep 2025; status: recruiting.
02
Drugs
puxitatug samrotecan
03
Conditions
endometrial cancer (EC)endometrial carcinosarcoma
Beyond the preview
Go deeper on jRCT2011250034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011250034.